 Meet Dr Joao Conde @CNanolab ⭐An ACS Materials Au 2022 Rising Star⭐The main focus of our research is the use of Cancer Nanotechnology for Precision Medicine in order to tackle crucial medical problems involved in the development of novel and highly effective diagnostic and therapy platforms for cancer. (J. Conde) |  World’s Top 2% Scientists listSo happy and honored to be part of the "World’s Top 2% Scientists list" by Stanford University as scientists with the most impact in 2021. Thank you so much to all @CNanolab, NOVA Medical School - Faculdade de Ciências Médicas, Universidade Nova de Lisboa and collaborators around the world who helped make this achievement possible |  Presentation @COLife community meeting 2022the COLife Community Meeting 2022 aims to bring together directors, group leaders, postdocs, students, technicians, staff and heads of facilities and technical platforms, all members of our community, who are eager to share their experience and know-how. |
---|
 NOVA Sustainability Week 2022Round-table conversation at Universidade Nova de Lisboa in NOVA SUSTAINABILITY WEEK - Nova Medical School #NMSResearch |  Forbes - Study Evaluates Global Burden Of Cancer Based On Preventable Risk FactorsThis past week, The Lancet published findings reported by the “Global Burden of Disease Study 2019,” elucidating which preventable risks impact both cancer-related illness and cancer-related death throughout the world. The study group, which collected data from multiple publicly-accessible vital registry databases globally, analyzed both cancer-related deaths as well as cancer-related disease burden over the period 2010-2019. |  What are the standards for Nanomedicine?This research was performed in collaboration with Technion — Israel Institute of Technology, iChEM from University of Science and Technology of China and the Center for Nanomedicine and Department of Anesthesiology from Harvard Medical School.
The full article, Nanodelivery of nucleic acids, can be found in Nature Reviews Methods Primers journal. It was also highlighted by the journal in the feature PrimeView. |
---|
 CEDOC joins consortium aiming to fight inequalities in health access worldwideJoão Conde, leader of the Cancer NanoMedicine lab at CEDOC, is one of the contributors of a new The Lancet publication on Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. |  Diário de Noticias - João CondeJoão Conde, professor de Genética, investigador do Centro de Estudos de Ciências Médicas (ToxOmics), da Faculdade de Ciências Médicas, Universidade Nova de Lisboa, defende que as farmacêuticas devem apoiar a investigação e que a nanomedicina é uma aposta de futuro. |  A new meta-analysis sheds light on the progress of nanotechnology across the globeJoão Conde, from the Cancer Nanomedicine lab at CEDOC, just published a meta-analysis on the progress and investment in nanotechnology, alongside colleagues from iMed from Universidade de Lisboa and i3S from Universidade do Porto, MIT (United States of America) and University of Wollongong (Australia). The research was published on ACS Nano with the title “Facts and Figures on Materials Science and Nanotechnology Progress and Investment”. |
---|
 Nanomaterials 2020 Young Investigator AwardMDPI, Nanomaterials Journal |  CEDOC researchers stand out in the top 2% of the most cited authors in their fieldCEDOC researchers Miguel Seabra, principal investigator of Molecular Mechanisms of Disease group, Pedro Póvoa, from Integrated Pathophysiological Mechanisms group, and Winchil Vaz, from Lysosomes in Chronic Human Pathology and Infection group, integrate the group of the most cited scientists worldwide in different disciplines, ranking in the top 2% in their respective fields. João Conde, from Cancer Nanomedicine group, presently working at CEDOC, also integrates this list. |  Q&A Spotlight on early-career researchersNature Communications Biology - “Swallowing the doctor”: an interview with João Conde about the future of nanomedicine |
---|